Clinical trial NCT03081273: Corynebacterium Spp Bone and Joint Infection: Retrospective Study of Microbiological, Diagnostic and Therapeutic Features
Official title: Corynebacterium Spp Bone and Joint Infection: Retrospective Study of Microbiological, Diagnostic and Therapeutic Features
Study type: OBSERVATIONAL
Overall status: COMPLETED
Conditions: Corynebacterium Infections
Keywords: Antimicrobial susceptibility
Biofilm formation
Bone and joint infection
Corynebacterium spp
Osteoblast
Outcome
Prosthetic joint infection
Lead sponsor: Hospices Civils de Lyon
Sponsor class: OTHER
First posted: 2017-03-16
Enrollment: 49
Sex: ALL
Minimum age (years): 18
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Observational model: COHORT
Time perspective: RETROSPECTIVE
Sampling method: NON_PROBABILITY_SAMPLE
Study population: patients with microbiologically proven Corynebacterium bone and joint infection.

Brief summary: Corynebacterium spp have been considered as innocuous commensals of human skin, but are now accepted as important opportunistic pathogens responsible for various nosocomial infections, especially implicating foreign materials. In particular, they accounted for up to 10% of prosthetic joint infection (PJI), and are mostly identified in chronic forms of bone and joint infections (BJI). However, little is known about the pathophysiological pathway implicated in Corynebacterium BJI, species distribution and antimicrobial susceptibility, and the management of these difficult-to-treat clinical entities.

This study aims to report a retrospective cohort of patients with Corynebacterium spp BJI, aiming to : i) describe microbiological characteristics of the implicated clinical isolates, including species identification and antimicrobial susceptibility (and especially according to previous antimicrobial exposure); ii) assess pathophysiological mechanisms associated with BJI chronicity, including biofilm formation and bone cell invasion, to better understand mechanisms of Corynebacterium spp and to evaluate their ability to distinguished colonizing and infective isolates; iii) describe the medical (nature and duration of antimicrobial therapy) and surgical management of these patients; and iv) evaluate the patient outcome according to this management strategy, and highlight risk factor for treatment failure in order to improve patient's management.


Eligibility criteria: Inclusion Criteria:

* Adult patients (i.e age ≥ 18-year-old) with microbiologically proven Corynebacterium bone and joint infection, with or without implant

Exclusion Criteria:

* diabetic foot osteomyelitis
* pressure ulcer-associated osteomyelitis

Primary outcomes:
measure: Description of microbiological features of Corynebacterium infection
timeFrame: at diagnosis
measure: antimicrobial susceptibility
timeFrame: at diagnosis
Secondary outcomes:
measure: ability of clinical isolate to form biofilm
timeFrame: at diagnosis
measure: Corynebacterium isolate ability to invade and persist within bone cells
timeFrame: at diagnosis
measure: Surgical management and antimicrobial therapy in patients with bone or joint infection
timeFrame: at the end of follow up
measure: Treatment failure in patients with bone or joint infection
timeFrame: one to two years after the end of antimicrobial therapy
Other outcomes:
Locations:
city: Lyon
country: France
facility: Centre de reference des infections ostéo-articulaires- Hôpital de la Croix Rousse
Study officials:
affiliation: Centre de reference des infections ostéo-articulaires de Lyon
name: Tristan Ferry, MD,PhD
role: PRINCIPAL_INVESTIGATOR
References: